Beyond R-CHOP-21: What's New in Diffuse Large B-Cell Lymphoma

Susan R. Peck, PhD
Published: Thursday, Apr 19, 2012
Dr. John Leonard

John Leonard, MD

The current standard for patients with advanced diffuse large B-cell lymphoma (DLBCL) is R-CHOP-21 (21-day rituximab-cyclophosphamidedoxorubicin- vincristine-prednisone). However, while this regimen cures approximately two-thirds of patients, a significant fraction of patients will still relapse, and the prognosis for these patients is poor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication